8-K current report · filed Sep 15, 2026

Beta Bionics, Inc. (BBNX) 8-K Current Report: September 15, 2026

Item 8.01Item EX-99.1Item EX-99.2Item 7.01BBNX overview

Short answer

Beta Bionics, Inc. (BBNX) filed an 8-K current report with the SEC on September 15, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 7.01 (Regulation FD Disclosure). FDA clearance for Mint patch pump, enabling potential U.S. commercialization.

Beta Bionics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • FDA clearance for Mint patch pump, enabling potential U.S. commercialization
  • 510(k) submission for 3D Intelligence dosing algorithm, advancing regulatory review
  • Updated corporate presentation, providing additional company and product information

Item 8.01 · Other Events

  • FDA-cleared Mint expands Beta Bionics’ commercial platform, with U.S. launch targeted for Q1 2027
  • Planned 2027 capacity of at least 1.5 million disposable units supports potential scale, but execution remains unproven
  • Pharmacy-only launch initially reaches approximately 40% of insured U.S. lives, targeted to reach at least 50% within one year
  • 3D Intelligence 510(k) submission creates regulatory catalysts for iLet 3D by year-end 2026 and Mint 3D alongside Mint launch
  • Securities class action alleges iLet safety, efficacy and commercial-success misstatements, creating litigation costs and management distraction risk

Item EX-99.1 · Exhibit EX-99.1

  • FDA clearance for Mint enables U.S. commercialization, targeted for Q1 2027 through the pharmacy channel
  • 2027 manufacturing capacity targets at least 1.5 million disposable units, supporting potential scale-up
  • 3D Intelligence submitted via 510(k); iLet 3D expected by end-2026 and Mint 3D in Q1 2027, pending clearance
  • 2026 revenue guidance reduced to $121M–$126M from $131M–$136M, reflecting potential fourth-quarter deferrals up to $10M
  • 2026 gross-margin guidance reaffirmed at 58.5%–59.5%; Mint expected modestly dilutive in 2027 but accretive at scale

Item EX-99.2 · Exhibit EX-99.2

  • Q2’26 net sales $32.0M, gross margin 59.0%, with 69% of new starts from MDI patients
  • High-30s% of Q2’26 new starts reimbursed through pharmacy, validating Beta Bionics’ lower-friction distribution strategy
  • Mint patch pump FDA-cleared in September 2026, with full U.S. commercial launch targeted for Q1’27
  • 3D Intelligence 510(k) submitted, targeting iLet 3D commercialization by end-2026 and Mint 3D in Q1’27
  • T2D indication expansion targeted around mid-2027, potentially opening the underpenetrated primary-care and insulin-intensive T2D markets

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Beta Bionics, Inc. 8-K filings

Get the next BBNX 8-K as it lands

Follow BBNX for push alerts, or ask the research agent what this filing means.